期刊文献+

基于四氢喹啉酸骈环戊烯骨架的蛋白酪氨酸磷酸酶1B抑制剂的设计、合成及构效关系 被引量:3

Discovery and Structure-activity Relationships of Tetrahydro-3H-cyclopenta[c]quinolines Scaffold-based Potential PTP1B Inhibitors
下载PDF
导出
摘要 基于肿瘤、糖尿病等重大疾病的有限目标,选择蛋白酪氨酸磷酸酶(PTPs)家族这一生物体系中有代表性的PTP家族成员PTP1B,SHP-1,SHP-2,LAR,CDC25B及PRL-3进行研究.通过综合高通量筛选获得的"苗头"化合物结构信息,分析得到四氢喹啉骈环戊烯骨架.初步的构效关系研究表明,四氢喹啉酸骈环戊烯母核结构可作为PTPs抑制剂的基本骨架用于下一步的化学修饰.通过对34个化合物的设计、合成及构效关系的研究发现,四氢喹啉酸骈环戊烯的苯环8-位含有较大疏水取代基的化合物显示出对PTP1B较强的抑制活性和较高的选择性,其中,化合物31和35对PTP1B的抑制活性IC50分别达0.4和0.6μmol/L,并且对CDC25B,SHP1及SHP2显示出30倍以上的选择性. The protein tyrosine phosphatases(PTPs) constitute a family of closely related key regulatory enzymes that dephosphorylate phosphotyrosine residues in their protein substrates.Malfunctions in PTP activity are linked to various diseases,ranging from cancer to neurological disorders and diabetes.As part of a project aimed at identifying small molecular inhibitors based on PTPs family,focusing on diabetes mellitus,tumorigenesis,and infection,we performed the high-throughput screening(HTS) of a library of 48000 synthetic compounds for six representative PTPs,including PTP1B,SHP-1,SHP-2,PRL-3,CDC25B and LAR,and 3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline analogues were identified as PTPs inhibitors.Keeping the core template complete,we began the modification of benzene ring,intending to find out the best modifying position in benzene ring and the proper amount of substitutions on it.Consequently,thirty-four compounds were designed and synthesized,and careful structure-activity relationship(SAR) study with respect to PTP1B,SHP-1,SHP-2,PRL-3,CDC25B and LAR was carried out.Finally,it was found that the compounds bearing a bulky substituent at 8-position of the cyclopentaquinoline acid turned out to be PTP1B inhibitors with good potency and selectivity against other assayed PTPs.The most potent PTP1B inhibitor in this series,compounds 31 and 35,show good activity(IC50=0.4 and 0.6 μmol/L,respectively) and excellent selectivity for PTP1B over SHP-1,SHP-2,PRL-3 and LAR,and 30-fold selectivity over CDC25B.Due to time limit,the modification of core template is not sufficient enough,and it would be the direction of our further work to discover more potent core structures.
出处 《高等学校化学学报》 SCIE EI CAS CSCD 北大核心 2011年第2期306-315,共10页 Chemical Journal of Chinese Universities
基金 国家"八六三"计划项目(批准号:2006AA02Z315) 上海市科学技术委员会基金(批准号:08QH14005和08DZ2291300)资助
关键词 蛋白酪氨酸磷酸酶 高通量筛选 四氢喹啉酸骈环戊烯 抑制剂 Protein tyrosine phosphatase High-throughput screening Tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid Inhibitor
  • 相关文献

参考文献29

  • 1Hunter T.. Cell[J], 2000, 100( 1 ) : 113-127.
  • 2TonksN. K., NeelB. G.. Curr. Opin. Cell Biol.[J], 2001, 13(2):182--195.
  • 3Kappert K. , Peters K. G. , Btihmer F. D. , Ostman A.. Cardio. Vasc. Res. [J] , 2005, 65(3) : 587-598.
  • 4Stoker A. W.. J. Endocrinol. [J] , 2005, 185(1) : 19-33.
  • 5Tonks N. K.. Nature Reviews Molecular Cell Biology[J] , 2006, 7( 11 ) : 833-846.
  • 6WangW. J., KuoJ. C., KuW., Lee Y., Lin F., ChangY., Lin Y., Chen C., HuangY., ChiangM., et al.. Mol. Cell~J], 2007, 27(5): 701-716.
  • 7ZhangZ. Y.. Curr. Opin. Chem. Biol.[J], 2001, 5(4): 416-423.
  • 8van Huijsduijnen R. H. , Bombrun A. , Swinnen D.. Drugs Discovery Today[J] , 2002, 7(19) : 1013--1019.
  • 9Hendriks W. J. , Elson A. , Harroch S. , Stoker A. W.. FEBS J. [J] , 2008, 275(5) : 816--830.
  • 10Julien S. G.. Nat. Genet. [J], 2007, 39(3) : 338--346.

二级参考文献11

共引文献4

同被引文献65

  • 1任晓岚,汪鑫,李志裕,尤启冬.表皮生长因子受体(EGFR)酪氨酸激酶抑制剂的研究进展[J].中国新药杂志,2005,14(7):821-826. 被引量:31
  • 2罗弟祥,何耀,高小平,张义正.蛋白酪氨酸磷酸酶1B抑制剂高通量筛选模型建立和应用[J].天然产物研究与开发,2005,17(5):606-609. 被引量:10
  • 3周梅,章威,成元华,计明娟,徐筱杰.酪氨酸蛋白磷酸酯酶1B抑制剂的分子对接和三维定量构效关系研究[J].化学学报,2005,63(23):2131-2136. 被引量:7
  • 4Tonks N K, Diltz C D, Fischer E H. Purification of the major protein- tyrosine-phosphatases of human placenta [J]. The Journal of Biological Chemistry, 1988, 263(14): 6722-6730.
  • 5Walchli S, Curchod M L, Gobert R P, et ol. Identification of tyrosine phosphatasesthat dephosphorylate insulin receptor. A brute force approach based on "substratetrapping" mutants [J]. The Journ01 of Biological Chemistry, 2000, 275(13): 9792-9796.
  • 6Charbonneau H, Tonks N K, Kumar S, et al. Human placenta protein- tyrosine phosphatase: Amino-acid sequence and relationship to a family of receptor-like proteins [J]. Proceedings of the National Academy of Sciences USA, 1990, 86(14): 5152-5256.
  • 7Frangioni J V, Beahm P H, Shifrin V, et al. The nontransmembrane tyrosine phosphatase PTP-I B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence[J]. Cell, 1992, 68(3): 545-560.
  • 8Cicirelli M F, Tonks N K, Diltz C D, et al. Microinjection of a protein- tyrosine phosphatase inhibits insulin action in Xenopus oocytes [J]. Proceedings of the National Academy of Sciences USA, 1990, 87(14): 5514-5517.
  • 9Elchebly M, Payette P, Michaliszyn E, et ol. Increased insulin sensitivity and obesity resistance in Mice lacking the protein tyrosine phosphatase- 1B[J]. Science, 1999, 283(5407): 1544-1548.
  • 10Xie I, Lee S Y, Andersen J N, et al. Cellular effects of small molecule PTP-1B inhibitors on insulin signaling [J]. Biochemistry, 2003, 42(44): 12792-12804.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部